Driving Innovation in the HIV Clinical Trials Market
The global HIV clinical trials market was valued at USD 1.56 billion in 2024 and is expected to reach USD 2.11 billion by 2030, expanding at a CAGR of 5.8% from 2025 to 2030. This steady growth is underpinned by a surge in drug approvals targeting HIV, escalating R&D investments by pharmaceutical and biotech firms, and a rising prevalence of HIV worldwide. Clinical trials are also at the forefront of developing novel therapies—including precision medicines and vaccines—that enhance patient outcomes and help curb global incidence rates. As the landscape evolves, companies are increasingly focused on improving treatment adherence, innovating long‑acting drug formulations, and pursuing curative strategies, all while tailoring approaches to diverse patient populations. A parallel push to broaden access to these treatments further fuels expansion, creating ample opportunity for continued market advancement. Recent years have seen significant drug...